FDA approves Sunovion's lung disease drug

BY Grant Welker

Marlborough-based Sunovion said its newly approved drug is the first of its kind that's used to treat COPD.

Sunovion Pharmaceutics of Marlborough has received U.S. Food and Drug Administration approval for a new drug treating COPD, or chronic obstructive pulmonary disease.
The drug, Lonhala Magnair, is expected to be available in pharmacies in early 2018, Sunovion announced Thursday.
Lonhala Magnair, an inhalation solution, is the first long-acting muscarinic antagonist to be approved for treating COPD, according to Sunovion. The solution, which is to be used twice daily, works in two to three minutes and allows people with COPD to breathe normally.
An estimated 15.7 million adults in the United States have been diagnosed with COPD, according to Sunovion. The disease, which is treatable and preventable, involves respiratory symptoms due to airway or lung abnormalities. The main risk factor is smoking tobacco.
In studies, those treated with Lonhala Magnair showed statistically significant and clinically important changes compared to a placebo, Sunovion said.